Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2863105,clearance,Increasing the dose from 0.5 to 5.0 mg produced a significant reduction in clearance from 11.6 +/- 2.5 to 2.9 +/- 1.0 ml X min-1.,The disposition of primaquine in the isolated perfused rat liver. Effect of dose size. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863105/),[ml] / [min],11.6,8418,DB01087,Primaquine
,2863105,clearance,Increasing the dose from 0.5 to 5.0 mg produced a significant reduction in clearance from 11.6 +/- 2.5 to 2.9 +/- 1.0 ml X min-1.,The disposition of primaquine in the isolated perfused rat liver. Effect of dose size. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863105/),[ml] / [min],2.9,8419,DB01087,Primaquine
,2863105,AUC,"This decrease was accompanied by a disproportionate increase in the value of AUC from 25.4 +/- 5.9 to 1128.6 +/- 575.7 micrograms X min X ml-1, elimination half-life from 33.2 +/- 10.7 to 413.0 +/- 239.3 min, and volume of distribution from 547.7 +/- 153.1 to 1489.0 +/- 249.0 ml.",The disposition of primaquine in the isolated perfused rat liver. Effect of dose size. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863105/),[min·μg] / [ml],25.4,8420,DB01087,Primaquine
,2863105,AUC,"This decrease was accompanied by a disproportionate increase in the value of AUC from 25.4 +/- 5.9 to 1128.6 +/- 575.7 micrograms X min X ml-1, elimination half-life from 33.2 +/- 10.7 to 413.0 +/- 239.3 min, and volume of distribution from 547.7 +/- 153.1 to 1489.0 +/- 249.0 ml.",The disposition of primaquine in the isolated perfused rat liver. Effect of dose size. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863105/),[min·μg] / [ml],1128.6,8421,DB01087,Primaquine
,2863105,elimination half-life,"This decrease was accompanied by a disproportionate increase in the value of AUC from 25.4 +/- 5.9 to 1128.6 +/- 575.7 micrograms X min X ml-1, elimination half-life from 33.2 +/- 10.7 to 413.0 +/- 239.3 min, and volume of distribution from 547.7 +/- 153.1 to 1489.0 +/- 249.0 ml.",The disposition of primaquine in the isolated perfused rat liver. Effect of dose size. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863105/),min,33.2,8422,DB01087,Primaquine
,2863105,elimination half-life,"This decrease was accompanied by a disproportionate increase in the value of AUC from 25.4 +/- 5.9 to 1128.6 +/- 575.7 micrograms X min X ml-1, elimination half-life from 33.2 +/- 10.7 to 413.0 +/- 239.3 min, and volume of distribution from 547.7 +/- 153.1 to 1489.0 +/- 249.0 ml.",The disposition of primaquine in the isolated perfused rat liver. Effect of dose size. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863105/),min,413.0,8423,DB01087,Primaquine
,2863105,volume of distribution,"This decrease was accompanied by a disproportionate increase in the value of AUC from 25.4 +/- 5.9 to 1128.6 +/- 575.7 micrograms X min X ml-1, elimination half-life from 33.2 +/- 10.7 to 413.0 +/- 239.3 min, and volume of distribution from 547.7 +/- 153.1 to 1489.0 +/- 249.0 ml.",The disposition of primaquine in the isolated perfused rat liver. Effect of dose size. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863105/),ml,547.7,8424,DB01087,Primaquine
,2863105,volume of distribution,"This decrease was accompanied by a disproportionate increase in the value of AUC from 25.4 +/- 5.9 to 1128.6 +/- 575.7 micrograms X min X ml-1, elimination half-life from 33.2 +/- 10.7 to 413.0 +/- 239.3 min, and volume of distribution from 547.7 +/- 153.1 to 1489.0 +/- 249.0 ml.",The disposition of primaquine in the isolated perfused rat liver. Effect of dose size. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863105/),ml,1489.0,8425,DB01087,Primaquine
,8036681,maximum plasma concentration,"Mean values (SD in parentheses) of maximum plasma concentration of 57.7 (7.7) vs. 55.7 (7.4) ng/mL were reached at 2.2 (0.6) vs. 2.2 (0.6) h, for the G6PD deficient and G6PD normal groups, respectively.",Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8036681/),[ng] / [ml],57.7,11359,DB01087,Primaquine
,8036681,maximum plasma concentration,"Mean values (SD in parentheses) of maximum plasma concentration of 57.7 (7.7) vs. 55.7 (7.4) ng/mL were reached at 2.2 (0.6) vs. 2.2 (0.6) h, for the G6PD deficient and G6PD normal groups, respectively.",Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8036681/),[ng] / [ml],55.7,11360,DB01087,Primaquine
,8036681,t1/2 lambda,"Thereafter, drug levels declined rapidly and monoexponentially with a t1/2 lambda of 6.4 (1.9) vs. 6.3 (2.7) h.",Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8036681/),h,6.4,11361,DB01087,Primaquine
,8036681,t1/2 lambda,"Thereafter, drug levels declined rapidly and monoexponentially with a t1/2 lambda of 6.4 (1.9) vs. 6.3 (2.7) h.",Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8036681/),h,6.3,11362,DB01087,Primaquine
,8036681,MRT,"The respective mean values (SD in parentheses) for MRT, AUC0-varies; is directly proportional to Cl/f, and Vz/f were 6.8 (0.4) vs. 6.8 (0.5) h, 0.547 (0.070) vs. 0.521 (0.090) micrograms/h/mL, 8.54 (0.37) vs. 8.97 (1.46) mL/min/kg and 4.8 (1.7) vs. 5.1 (1.2) L/kg.",Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8036681/),h,6.8,11363,DB01087,Primaquine
,8036681,Vz/f,"The respective mean values (SD in parentheses) for MRT, AUC0-varies; is directly proportional to Cl/f, and Vz/f were 6.8 (0.4) vs. 6.8 (0.5) h, 0.547 (0.070) vs. 0.521 (0.090) micrograms/h/mL, 8.54 (0.37) vs. 8.97 (1.46) mL/min/kg and 4.8 (1.7) vs. 5.1 (1.2) L/kg.",Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8036681/),[ml] / [kg·min],8.54,11364,DB01087,Primaquine
,8036681,Vz/f,"The respective mean values (SD in parentheses) for MRT, AUC0-varies; is directly proportional to Cl/f, and Vz/f were 6.8 (0.4) vs. 6.8 (0.5) h, 0.547 (0.070) vs. 0.521 (0.090) micrograms/h/mL, 8.54 (0.37) vs. 8.97 (1.46) mL/min/kg and 4.8 (1.7) vs. 5.1 (1.2) L/kg.",Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8036681/),[ml] / [kg·min],8.97,11365,DB01087,Primaquine
,8036681,Vz/f,"The respective mean values (SD in parentheses) for MRT, AUC0-varies; is directly proportional to Cl/f, and Vz/f were 6.8 (0.4) vs. 6.8 (0.5) h, 0.547 (0.070) vs. 0.521 (0.090) micrograms/h/mL, 8.54 (0.37) vs. 8.97 (1.46) mL/min/kg and 4.8 (1.7) vs. 5.1 (1.2) L/kg.",Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8036681/),[l] / [kg],4.8,11366,DB01087,Primaquine
,8036681,Vz/f,"The respective mean values (SD in parentheses) for MRT, AUC0-varies; is directly proportional to Cl/f, and Vz/f were 6.8 (0.4) vs. 6.8 (0.5) h, 0.547 (0.070) vs. 0.521 (0.090) micrograms/h/mL, 8.54 (0.37) vs. 8.97 (1.46) mL/min/kg and 4.8 (1.7) vs. 5.1 (1.2) L/kg.",Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8036681/),[l] / [kg],5.1,11367,DB01087,Primaquine
,7957448,clearance time,No statistical difference was noted for clinical response except the gametocyte clearance time was shorter in children given MSP plus primaquine (7 +/- 2.7 days) than the children given MSP alone (21.9 +/- 4.4 days) (P < 0.01).,Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),d,7,23703,DB01087,Primaquine
,7957448,clearance time,No statistical difference was noted for clinical response except the gametocyte clearance time was shorter in children given MSP plus primaquine (7 +/- 2.7 days) than the children given MSP alone (21.9 +/- 4.4 days) (P < 0.01).,Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),d,21.9,23704,DB01087,Primaquine
,7957448,Cmax,Mean Cmax was 7.4 +/- 5.2 h in group I and 6.6 +/- 7.0 h in group II.,Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),h,7.4,23705,DB01087,Primaquine
,7957448,Cmax,Mean Cmax was 7.4 +/- 5.2 h in group I and 6.6 +/- 7.0 h in group II.,Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),h,6.6,23706,DB01087,Primaquine
,7957448,t1/2,"Mean t1/2, Cl/f and Vd/f were 9.8 +/- 1.6 days, 0.43 +/- 0.16 ml/min/kg and 8.84 +/- 4.21 l/kg in group I, 9.3 +/- 1.4 days, 0.41 +/- 0.12 ml/min/kg and 8.91 +/- 3.00 l/kg group II, respectively.",Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),d,9.8,23707,DB01087,Primaquine
,7957448,Cl/f,"Mean t1/2, Cl/f and Vd/f were 9.8 +/- 1.6 days, 0.43 +/- 0.16 ml/min/kg and 8.84 +/- 4.21 l/kg in group I, 9.3 +/- 1.4 days, 0.41 +/- 0.12 ml/min/kg and 8.91 +/- 3.00 l/kg group II, respectively.",Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),[ml] / [kg·min],0.43,23708,DB01087,Primaquine
,7957448,Cl/f,"Mean t1/2, Cl/f and Vd/f were 9.8 +/- 1.6 days, 0.43 +/- 0.16 ml/min/kg and 8.84 +/- 4.21 l/kg in group I, 9.3 +/- 1.4 days, 0.41 +/- 0.12 ml/min/kg and 8.91 +/- 3.00 l/kg group II, respectively.",Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),d,9.3,23709,DB01087,Primaquine
,7957448,Cl/f,"Mean t1/2, Cl/f and Vd/f were 9.8 +/- 1.6 days, 0.43 +/- 0.16 ml/min/kg and 8.84 +/- 4.21 l/kg in group I, 9.3 +/- 1.4 days, 0.41 +/- 0.12 ml/min/kg and 8.91 +/- 3.00 l/kg group II, respectively.",Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),[ml] / [kg·min],0.41,23710,DB01087,Primaquine
,7957448,Vd/f,"Mean t1/2, Cl/f and Vd/f were 9.8 +/- 1.6 days, 0.43 +/- 0.16 ml/min/kg and 8.84 +/- 4.21 l/kg in group I, 9.3 +/- 1.4 days, 0.41 +/- 0.12 ml/min/kg and 8.91 +/- 3.00 l/kg group II, respectively.",Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),[l] / [kg],8.84,23711,DB01087,Primaquine
,7957448,Vd/f,"Mean t1/2, Cl/f and Vd/f were 9.8 +/- 1.6 days, 0.43 +/- 0.16 ml/min/kg and 8.84 +/- 4.21 l/kg in group I, 9.3 +/- 1.4 days, 0.41 +/- 0.12 ml/min/kg and 8.91 +/- 3.00 l/kg group II, respectively.",Pharmacokinetic study of mefloquine in Thai children aged 5-12 years suffering from uncomplicated falciparum malaria treated with MSP or MSP plus primaquine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957448/),[l] / [kg],8.91,23712,DB01087,Primaquine
,25759576,oral bioavailability,"A microemulsion formulation of TQ (MTQ) with sizes <20 nm improved the solubility of TQ and enhanced the oral bioavailability from 55% to 99% in healthy mice (area under the curve 0 to infinity: 11,368±1,232 and 23,842±872 min·μmol/L) for reference TQ and MTQ, respectively.",Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25759576/),%,55,42852,DB01087,Primaquine
,25759576,oral bioavailability,"A microemulsion formulation of TQ (MTQ) with sizes <20 nm improved the solubility of TQ and enhanced the oral bioavailability from 55% to 99% in healthy mice (area under the curve 0 to infinity: 11,368±1,232 and 23,842±872 min·μmol/L) for reference TQ and MTQ, respectively.",Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25759576/),%,99,42853,DB01087,Primaquine
,25759576,area under the curve 0 to infinity,"A microemulsion formulation of TQ (MTQ) with sizes <20 nm improved the solubility of TQ and enhanced the oral bioavailability from 55% to 99% in healthy mice (area under the curve 0 to infinity: 11,368±1,232 and 23,842±872 min·μmol/L) for reference TQ and MTQ, respectively.",Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25759576/),[min·μM] / [l],"11,368",42854,DB01087,Primaquine
,25759576,area under the curve 0 to infinity,"A microemulsion formulation of TQ (MTQ) with sizes <20 nm improved the solubility of TQ and enhanced the oral bioavailability from 55% to 99% in healthy mice (area under the curve 0 to infinity: 11,368±1,232 and 23,842±872 min·μmol/L) for reference TQ and MTQ, respectively.",Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25759576/),[min·μM] / [l],"23,842",42855,DB01087,Primaquine
,1820639,area under the curve (AUC),"The mean values (+/- SD) of area under the curve (AUC) of the last dose were significantly decreased when compared to the values of the first dose both in whole blood and in plasma (909.96 +/- 603.07, 1,147.05 +/- 684.8 ng.hr/ml respectively in whole blood with p = 0.007 and 1,255.11 +/- 531.59, 1,603.66 +/- 505.45 ng.hr/ml respectively in plasma with p = 0.023).",Pharmacokinetics of primaquine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820639/),[h·ng] / [ml],909.96,43754,DB01087,Primaquine
,1820639,area under the curve (AUC),"The mean values (+/- SD) of area under the curve (AUC) of the last dose were significantly decreased when compared to the values of the first dose both in whole blood and in plasma (909.96 +/- 603.07, 1,147.05 +/- 684.8 ng.hr/ml respectively in whole blood with p = 0.007 and 1,255.11 +/- 531.59, 1,603.66 +/- 505.45 ng.hr/ml respectively in plasma with p = 0.023).",Pharmacokinetics of primaquine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820639/),[h·ng] / [ml],"1,147.05",43755,DB01087,Primaquine
,1820639,area under the curve (AUC),"The mean values (+/- SD) of area under the curve (AUC) of the last dose were significantly decreased when compared to the values of the first dose both in whole blood and in plasma (909.96 +/- 603.07, 1,147.05 +/- 684.8 ng.hr/ml respectively in whole blood with p = 0.007 and 1,255.11 +/- 531.59, 1,603.66 +/- 505.45 ng.hr/ml respectively in plasma with p = 0.023).",Pharmacokinetics of primaquine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820639/),[h·ng] / [ml],"1,255.11",43756,DB01087,Primaquine
,1820639,area under the curve (AUC),"The mean values (+/- SD) of area under the curve (AUC) of the last dose were significantly decreased when compared to the values of the first dose both in whole blood and in plasma (909.96 +/- 603.07, 1,147.05 +/- 684.8 ng.hr/ml respectively in whole blood with p = 0.007 and 1,255.11 +/- 531.59, 1,603.66 +/- 505.45 ng.hr/ml respectively in plasma with p = 0.023).",Pharmacokinetics of primaquine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820639/),[h·ng] / [ml],"1,603.66",43757,DB01087,Primaquine
,1820639,clearance,"The decrease in the concentration-time profile of the last dose was due to enhancement of drug elimination with significant increase in clearance after the last dose (4.871 +/- 1.741 and 6.443 +/- 2.514 ml/min/kg respectively in whole blood with p = 0.007, 3.199 +/- 1.197 and 4.422 +/- 2.068 ml/min/kg respectively in plasma with p = 0.016).",Pharmacokinetics of primaquine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820639/),[ml] / [kg·min],4.871,43758,DB01087,Primaquine
,1820639,clearance,"The decrease in the concentration-time profile of the last dose was due to enhancement of drug elimination with significant increase in clearance after the last dose (4.871 +/- 1.741 and 6.443 +/- 2.514 ml/min/kg respectively in whole blood with p = 0.007, 3.199 +/- 1.197 and 4.422 +/- 2.068 ml/min/kg respectively in plasma with p = 0.016).",Pharmacokinetics of primaquine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820639/),[ml] / [kg·min],6.443,43759,DB01087,Primaquine
,1820639,clearance,"The decrease in the concentration-time profile of the last dose was due to enhancement of drug elimination with significant increase in clearance after the last dose (4.871 +/- 1.741 and 6.443 +/- 2.514 ml/min/kg respectively in whole blood with p = 0.007, 3.199 +/- 1.197 and 4.422 +/- 2.068 ml/min/kg respectively in plasma with p = 0.016).",Pharmacokinetics of primaquine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820639/),[ml] / [kg·min],3.199,43760,DB01087,Primaquine
,1820639,clearance,"The decrease in the concentration-time profile of the last dose was due to enhancement of drug elimination with significant increase in clearance after the last dose (4.871 +/- 1.741 and 6.443 +/- 2.514 ml/min/kg respectively in whole blood with p = 0.007, 3.199 +/- 1.197 and 4.422 +/- 2.068 ml/min/kg respectively in plasma with p = 0.016).",Pharmacokinetics of primaquine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820639/),[ml] / [kg·min],4.422,43761,DB01087,Primaquine
,17410524,Clearance,Clearance was higher in rats (3.2 l/h/kg) than in rabbits and monkeys (1.2 l/h/kg) and it was found be negligibly excreted in rat urine and feces.,"In Vitro and In Vivo pharmacokinetic studies of bulaquine (analogue of primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey--highlighting species similarities and differences. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410524/),[l] / [h·kg],3.2,57597,DB01087,Primaquine
,17410524,Clearance,Clearance was higher in rats (3.2 l/h/kg) than in rabbits and monkeys (1.2 l/h/kg) and it was found be negligibly excreted in rat urine and feces.,"In Vitro and In Vivo pharmacokinetic studies of bulaquine (analogue of primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey--highlighting species similarities and differences. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410524/),[l] / [h·kg],1.2,57598,DB01087,Primaquine
,17410524,elimination half-life,The elimination half-life in rats and rabbits was comparable after both oral and i.v. administration ( approximately 1.2 h).,"In Vitro and In Vivo pharmacokinetic studies of bulaquine (analogue of primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey--highlighting species similarities and differences. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410524/),h,1.2,57599,DB01087,Primaquine
,17410524,oral bioavailability,"The oral bioavailability of BQ was 3.12%, 5.3% and 12% in rats, rabbits and monkeys, respectively, which could be mainly due to the high instability of BQ at acidic pH as demonstrated from a simulated gastric fluid stability study.","In Vitro and In Vivo pharmacokinetic studies of bulaquine (analogue of primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey--highlighting species similarities and differences. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410524/),%,3.12,57600,DB01087,Primaquine
,17410524,oral bioavailability,"The oral bioavailability of BQ was 3.12%, 5.3% and 12% in rats, rabbits and monkeys, respectively, which could be mainly due to the high instability of BQ at acidic pH as demonstrated from a simulated gastric fluid stability study.","In Vitro and In Vivo pharmacokinetic studies of bulaquine (analogue of primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey--highlighting species similarities and differences. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410524/),%,5.3,57601,DB01087,Primaquine
,17410524,oral bioavailability,"The oral bioavailability of BQ was 3.12%, 5.3% and 12% in rats, rabbits and monkeys, respectively, which could be mainly due to the high instability of BQ at acidic pH as demonstrated from a simulated gastric fluid stability study.","In Vitro and In Vivo pharmacokinetic studies of bulaquine (analogue of primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey--highlighting species similarities and differences. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410524/),%,12,57602,DB01087,Primaquine
,17410524,partition coefficient,"Protein binding in various species was in the range 50-65% while the partition coefficient between RBCs and plasma (K(rbc/pl)) was between 0.75 and 1, indicating significant RBC uptake.","In Vitro and In Vivo pharmacokinetic studies of bulaquine (analogue of primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey--highlighting species similarities and differences. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17410524/),,0.75 and 1,57603,DB01087,Primaquine
,20929590,PCT,Parasite clearance time (PCT) and fever clearance time (FCT) were significantly prolonged in patients with treatment failure compared with those with sensitive response [median (95% CI) values for PCT 32.0 (20.0-48.0) vs 24.0 (14.0-32.0) hr and FCT 30.0 (22.0-42.0) vs 26.0 (18.0-36.0) hr; p < 0.005].,Declining in efficacy of a three-day combination regimen of mefloquine-artesunate in a multi-drug resistance area along the Thai-Myanmar border. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20929590/),h,32.0,60948,DB01087,Primaquine
,20929590,PCT,Parasite clearance time (PCT) and fever clearance time (FCT) were significantly prolonged in patients with treatment failure compared with those with sensitive response [median (95% CI) values for PCT 32.0 (20.0-48.0) vs 24.0 (14.0-32.0) hr and FCT 30.0 (22.0-42.0) vs 26.0 (18.0-36.0) hr; p < 0.005].,Declining in efficacy of a three-day combination regimen of mefloquine-artesunate in a multi-drug resistance area along the Thai-Myanmar border. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20929590/),h,24.0,60949,DB01087,Primaquine
,20929590,FCT,Parasite clearance time (PCT) and fever clearance time (FCT) were significantly prolonged in patients with treatment failure compared with those with sensitive response [median (95% CI) values for PCT 32.0 (20.0-48.0) vs 24.0 (14.0-32.0) hr and FCT 30.0 (22.0-42.0) vs 26.0 (18.0-36.0) hr; p < 0.005].,Declining in efficacy of a three-day combination regimen of mefloquine-artesunate in a multi-drug resistance area along the Thai-Myanmar border. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20929590/),h,30.0,60950,DB01087,Primaquine
,20929590,FCT,Parasite clearance time (PCT) and fever clearance time (FCT) were significantly prolonged in patients with treatment failure compared with those with sensitive response [median (95% CI) values for PCT 32.0 (20.0-48.0) vs 24.0 (14.0-32.0) hr and FCT 30.0 (22.0-42.0) vs 26.0 (18.0-36.0) hr; p < 0.005].,Declining in efficacy of a three-day combination regimen of mefloquine-artesunate in a multi-drug resistance area along the Thai-Myanmar border. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20929590/),h,26.0,60951,DB01087,Primaquine
,25637634,Peak (-)-(R)-PQ concentrations,"Peak (-)-(R)-PQ concentrations ranged from 121 ng/ml to 221 ng/ml, and peak (+)-(S)-PQ concentrations ranged from 168 ng/ml to 299 ng/ml.",Enantioselective pharmacokinetics of primaquine in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637634/),[ng] / [ml],121,70503,DB01087,Primaquine
,25637634,Peak (-)-(R)-PQ concentrations,"Peak (-)-(R)-PQ concentrations ranged from 121 ng/ml to 221 ng/ml, and peak (+)-(S)-PQ concentrations ranged from 168 ng/ml to 299 ng/ml.",Enantioselective pharmacokinetics of primaquine in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637634/),[ng] / [ml],221,70504,DB01087,Primaquine
,25637634,peak (+)-(S)-PQ concentrations,"Peak (-)-(R)-PQ concentrations ranged from 121 ng/ml to 221 ng/ml, and peak (+)-(S)-PQ concentrations ranged from 168 ng/ml to 299 ng/ml.",Enantioselective pharmacokinetics of primaquine in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637634/),[ng] / [ml],168,70505,DB01087,Primaquine
,25637634,peak (+)-(S)-PQ concentrations,"Peak (-)-(R)-PQ concentrations ranged from 121 ng/ml to 221 ng/ml, and peak (+)-(S)-PQ concentrations ranged from 168 ng/ml to 299 ng/ml.",Enantioselective pharmacokinetics of primaquine in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637634/),[ng] / [ml],299,70506,DB01087,Primaquine
,25637634,peak concentrations,"The peak concentrations of (-)-cPQ were observed at 8 hours (range: 1104-1756 ng/ml); however, very high concentrations were sustained through 24 hours.",Enantioselective pharmacokinetics of primaquine in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637634/),[ng] / [ml],1104-1756,70507,DB01087,Primaquine
,1808614,Vss/f,"Model parameters (mean +/- SD) included a Vss/f of 18.5 +/- 2.8 L/kg, CL/f of 83 +/- 24 ml/hr/kg, terminal elimination t1/2 of 169.7 +/- 52.0 hr, t1/2keo of 123.0 +/- 22.4 hr, an Emax of 31.3 +/- 15.9% MHb, an EC50 of 596 +/- 128 ng/ml, and a sigmoidicity coefficient (n) of 1.94 +/- 0.47.",Simultaneous modeling of the pharmacokinetics and methemoglobin pharmacodynamics of an 8-aminoquinoline candidate antimalarial (WR 238605). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1808614/),[l] / [kg],18.5,76971,DB01087,Primaquine
,1808614,CL/f,"Model parameters (mean +/- SD) included a Vss/f of 18.5 +/- 2.8 L/kg, CL/f of 83 +/- 24 ml/hr/kg, terminal elimination t1/2 of 169.7 +/- 52.0 hr, t1/2keo of 123.0 +/- 22.4 hr, an Emax of 31.3 +/- 15.9% MHb, an EC50 of 596 +/- 128 ng/ml, and a sigmoidicity coefficient (n) of 1.94 +/- 0.47.",Simultaneous modeling of the pharmacokinetics and methemoglobin pharmacodynamics of an 8-aminoquinoline candidate antimalarial (WR 238605). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1808614/),[ml] / [h·kg],83,76972,DB01087,Primaquine
,1808614,terminal elimination t1/2,"Model parameters (mean +/- SD) included a Vss/f of 18.5 +/- 2.8 L/kg, CL/f of 83 +/- 24 ml/hr/kg, terminal elimination t1/2 of 169.7 +/- 52.0 hr, t1/2keo of 123.0 +/- 22.4 hr, an Emax of 31.3 +/- 15.9% MHb, an EC50 of 596 +/- 128 ng/ml, and a sigmoidicity coefficient (n) of 1.94 +/- 0.47.",Simultaneous modeling of the pharmacokinetics and methemoglobin pharmacodynamics of an 8-aminoquinoline candidate antimalarial (WR 238605). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1808614/),h,169.7,76973,DB01087,Primaquine
,1808614,t1/2keo,"Model parameters (mean +/- SD) included a Vss/f of 18.5 +/- 2.8 L/kg, CL/f of 83 +/- 24 ml/hr/kg, terminal elimination t1/2 of 169.7 +/- 52.0 hr, t1/2keo of 123.0 +/- 22.4 hr, an Emax of 31.3 +/- 15.9% MHb, an EC50 of 596 +/- 128 ng/ml, and a sigmoidicity coefficient (n) of 1.94 +/- 0.47.",Simultaneous modeling of the pharmacokinetics and methemoglobin pharmacodynamics of an 8-aminoquinoline candidate antimalarial (WR 238605). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1808614/),h,123.0,76974,DB01087,Primaquine
,1808614,Emax,"Model parameters (mean +/- SD) included a Vss/f of 18.5 +/- 2.8 L/kg, CL/f of 83 +/- 24 ml/hr/kg, terminal elimination t1/2 of 169.7 +/- 52.0 hr, t1/2keo of 123.0 +/- 22.4 hr, an Emax of 31.3 +/- 15.9% MHb, an EC50 of 596 +/- 128 ng/ml, and a sigmoidicity coefficient (n) of 1.94 +/- 0.47.",Simultaneous modeling of the pharmacokinetics and methemoglobin pharmacodynamics of an 8-aminoquinoline candidate antimalarial (WR 238605). ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1808614/),%,31.3,76975,DB01087,Primaquine
,1808614,EC50,"Model parameters (mean +/- SD) included a Vss/f of 18.5 +/- 2.8 L/kg, CL/f of 83 +/- 24 ml/hr/kg, terminal elimination t1/2 of 169.7 +/- 52.0 hr, t1/2keo of 123.0 +/- 22.4 hr, an Emax of 31.3 +/- 15.9% MHb, an EC50 of 596 +/- 128 ng/ml, and a sigmoidicity coefficient (n) of 1.94 +/- 0.47.",Simultaneous modeling of the pharmacokinetics and methemoglobin pharmacodynamics of an 8-aminoquinoline candidate antimalarial (WR 238605). ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1808614/),[ng] / [ml],596,76976,DB01087,Primaquine
,6721990,peak,"After oral administration of 45 mg primaquine, to five healthy volunteers, absorption was rapid, with peak primaquine levels of 153.3 +/- 23.5 ng/ml at 3 +/- 1 h, followed by an elimination half-life of 7.1 +/- 1.6 h, systemic clearance of 21.1 +/- 7.1 l/h, volume of distribution of 205 +/- 371 and cumulative urinary excretion of 1.3 +/- 0.9% of the dose.",Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6721990/),[ng] / [m],153,77140,DB01087,Primaquine
,6721990,elimination half-life,"After oral administration of 45 mg primaquine, to five healthy volunteers, absorption was rapid, with peak primaquine levels of 153.3 +/- 23.5 ng/ml at 3 +/- 1 h, followed by an elimination half-life of 7.1 +/- 1.6 h, systemic clearance of 21.1 +/- 7.1 l/h, volume of distribution of 205 +/- 371 and cumulative urinary excretion of 1.3 +/- 0.9% of the dose.",Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6721990/),h,7.1,77141,DB01087,Primaquine
,6721990,systemic clearance,"After oral administration of 45 mg primaquine, to five healthy volunteers, absorption was rapid, with peak primaquine levels of 153.3 +/- 23.5 ng/ml at 3 +/- 1 h, followed by an elimination half-life of 7.1 +/- 1.6 h, systemic clearance of 21.1 +/- 7.1 l/h, volume of distribution of 205 +/- 371 and cumulative urinary excretion of 1.3 +/- 0.9% of the dose.",Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6721990/),[l] / [h],21.1,77142,DB01087,Primaquine
,6721990,volume of distribution,"After oral administration of 45 mg primaquine, to five healthy volunteers, absorption was rapid, with peak primaquine levels of 153.3 +/- 23.5 ng/ml at 3 +/- 1 h, followed by an elimination half-life of 7.1 +/- 1.6 h, systemic clearance of 21.1 +/- 7.1 l/h, volume of distribution of 205 +/- 371 and cumulative urinary excretion of 1.3 +/- 0.9% of the dose.",Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6721990/),,205,77143,DB01087,Primaquine
,6721990,peak levels,"Primaquine underwent rapid conversion to the carboxylic acid metabolite of primaquine, which achieved peak levels of 1427 +/- 307 ng/ml at 7 +/- 4 h.",Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6721990/),[ng] / [ml],1427,77144,DB01087,Primaquine
,9598455,tmax,"WR 238605 has a long absorption phase and is slowly metabolized, with a tmax of 12 hr and an elimination half-life of 14 days.","First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9598455/),h,12,80680,DB01087,Primaquine
,9598455,elimination half-life,"WR 238605 has a long absorption phase and is slowly metabolized, with a tmax of 12 hr and an elimination half-life of 14 days.","First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9598455/),d,14,80681,DB01087,Primaquine
,3542534,peak blood concentration,"After a single oral dose on Day 1, a mean peak blood concentration of 50.7 ng/ml PQ was attained after 2.3 h, which declined monoexponentially with a half-life of 5.6 h.",Pharmacokinetics of primaquine in patients with P. vivax malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542534/),[ng] / [ml],50.7,80918,DB01087,Primaquine
,3542534,half-life,"After a single oral dose on Day 1, a mean peak blood concentration of 50.7 ng/ml PQ was attained after 2.3 h, which declined monoexponentially with a half-life of 5.6 h.",Pharmacokinetics of primaquine in patients with P. vivax malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542534/),h,5.6,80919,DB01087,Primaquine
,3542534,total body clearance,The mean total body clearance was 37.6 l/h and the volume of distribution was 292 l.,Pharmacokinetics of primaquine in patients with P. vivax malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542534/),[l] / [h],37.6,80920,DB01087,Primaquine
,3542534,volume of distribution,The mean total body clearance was 37.6 l/h and the volume of distribution was 292 l.,Pharmacokinetics of primaquine in patients with P. vivax malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542534/),l,292,80921,DB01087,Primaquine
,3542534,renal clearance,The mean renal excretion (0-24 h) of the drug was only 0.54% of the dose and renal clearance was 0.189 l/h.,Pharmacokinetics of primaquine in patients with P. vivax malaria. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542534/),[l] / [h],0.189,80922,DB01087,Primaquine
,3542534,steady state blood concentration,"Following chronic administration, none of the pharmacokinetic parameters was affected, and a steady state blood concentration of 2.5-4.2 ng/ml PQ was attained.",Pharmacokinetics of primaquine in patients with P. vivax malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542534/),[ng] / [ml],2.5-4.2,80923,DB01087,Primaquine
,33827163,maximum plasma concentration,Mean maximum plasma concentration of primaquine phosphate was 277 ± 96 ng/ml at approximately 3.1 hr following oral administration.,PHARMACOKINETICS OF PRIMAQUINE PHOSPHATE AFTER A SINGLE ORAL ADMINISTRATION TO AFRICAN PENGUINS (SPHENISCUS DEMERSUS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33827163/),[ng] / [ml],277,86424,DB01087,Primaquine
,33827163,disappearance half-life,The mean disappearance half-life was 3.6 ± 1.6 hr.,PHARMACOKINETICS OF PRIMAQUINE PHOSPHATE AFTER A SINGLE ORAL ADMINISTRATION TO AFRICAN PENGUINS (SPHENISCUS DEMERSUS). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33827163/),h,3.6,86425,DB01087,Primaquine
,6976848,plasma elimination half-life,The plasma elimination half-life was about 4 h.,Studies on the pharmacokinetics of primaquine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6976848/),h,4,91171,DB01087,Primaquine
,15202566,maximum concentration,The maximum concentration of CPMQ was 0.32+/-0.13 microg/mL at 4 h.,Pharmacokinetics of primaquine and carboxyprimaquine in Korean patients with vivax malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15202566/),[μg] / [ml],0.32,99015,DB01087,Primaquine
,15202566,elimination half-life,"The elimination half-life was 3.76+/-1.8 h and 15.7+/-12.2 h, for PMQ and CPMQ, respectively.",Pharmacokinetics of primaquine and carboxyprimaquine in Korean patients with vivax malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15202566/),h,3.76,99016,DB01087,Primaquine
,15202566,elimination half-life,"The elimination half-life was 3.76+/-1.8 h and 15.7+/-12.2 h, for PMQ and CPMQ, respectively.",Pharmacokinetics of primaquine and carboxyprimaquine in Korean patients with vivax malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15202566/),h,15.7,99017,DB01087,Primaquine
,4027118,peak plasma concentrations,After acute dosage (15 mg p.o.) mean (+/- s.d.) peak plasma concentrations of 65.0 +/- 34.7 ng ml-1 were achieved within 2 +/- 1h.,Pharmacokinetics of primaquine in man. Comparison of acute vs chronic dosage in Thai subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027118/),[ng] / [ml],65.0,103156,DB01087,Primaquine
,4027118,elimination half life,Thereafter plasma drug concentrations declined monoexponentially with a mean elimination half life of 4.4 +/- 1.4 h.,Pharmacokinetics of primaquine in man. Comparison of acute vs chronic dosage in Thai subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027118/),h,4.4,103157,DB01087,Primaquine
,4027118,oral clearance,The mean (+/- s.d.) oral clearance was 37.6 +/- 15.5 1 h-1.,Pharmacokinetics of primaquine in man. Comparison of acute vs chronic dosage in Thai subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027118/),[1] / [h],37.6,103158,DB01087,Primaquine
>,12852456,recoveries,"The method was sensitive with a limit of quantitation of 20 ng ml(-1) in rabbit plasma for both BQ and PQ and the recoveries were > 85 and > 45%, respectively.",Analysis and pharmacokinetics of bulaquine and its major metabolite primaquine in rabbits using an LC-UV method--a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852456/),%,85,103514,DB01087,Primaquine
>,12852456,recoveries,"The method was sensitive with a limit of quantitation of 20 ng ml(-1) in rabbit plasma for both BQ and PQ and the recoveries were > 85 and > 45%, respectively.",Analysis and pharmacokinetics of bulaquine and its major metabolite primaquine in rabbits using an LC-UV method--a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852456/),%,45,103515,DB01087,Primaquine
,28526056,MIC,Pharmacokinetic simulations demonstrate that trough concentrations of TQ exceed the proposed MIC of 80 ng/ml in >95% of individuals.,The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28526056/),[ng] / [ml],80,105394,DB01087,Primaquine
,7255540,half-life,"The half-life of unmetabolized primaquine was 4.0 h in lung, 1.7-1.9 h in blood, spleen, kidney and heart, and 1.2 h in liver.",Tissue distribution of primaquine in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7255540/),h,4.0,105833,DB01087,Primaquine
,7255540,half-life,"The half-life of unmetabolized primaquine was 4.0 h in lung, 1.7-1.9 h in blood, spleen, kidney and heart, and 1.2 h in liver.",Tissue distribution of primaquine in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7255540/),h,1.7-1.9,105834,DB01087,Primaquine
,7255540,half-life,"The half-life of unmetabolized primaquine was 4.0 h in lung, 1.7-1.9 h in blood, spleen, kidney and heart, and 1.2 h in liver.",Tissue distribution of primaquine in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7255540/),h,1.2,105835,DB01087,Primaquine
,8212522,concentration,The extrapolated concentration of primaquine at zero time after IV administration was 0.50 +/- 0.48 microgram/ml (mean +/- SD) which decreased with an elimination half-life of 0.16 +/- 0.07 h.,The pharmacokinetics of primaquine in calves after subcutaneous and intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8212522/),[μg] / [ml],0.50,107946,DB01087,Primaquine
,8212522,elimination half-life,The extrapolated concentration of primaquine at zero time after IV administration was 0.50 +/- 0.48 microgram/ml (mean +/- SD) which decreased with an elimination half-life of 0.16 +/- 0.07 h.,The pharmacokinetics of primaquine in calves after subcutaneous and intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8212522/),h,0.16,107947,DB01087,Primaquine
,8212522,peak concentration,The peak concentration of carboxyprimaquine was 0.50 +/- 0.08 microgram/ml at 1.67 +/- 0.15 h after IV administration.,The pharmacokinetics of primaquine in calves after subcutaneous and intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8212522/),,0.50,107948,DB01087,Primaquine
,8212522,elimination half-lives,"The elimination half-lives of carboxyprimaquine after IV and SC administration were 15.06 +/- 0.99 and 12.26 +/- 3.06 h, respectively.",The pharmacokinetics of primaquine in calves after subcutaneous and intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8212522/),h,15.06,107949,DB01087,Primaquine
,8212522,elimination half-lives,"The elimination half-lives of carboxyprimaquine after IV and SC administration were 15.06 +/- 0.99 and 12.26 +/- 3.06 h, respectively.",The pharmacokinetics of primaquine in calves after subcutaneous and intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8212522/),h,12.26,107950,DB01087,Primaquine
,8212522,areas under the concentration-time curve,The areas under the concentration-time curve for carboxyprimaquine were similar following either IV or SC administration of primaquine; the values were 11.85 +/- 2.62 micrograms.h/ml after the former and 10.95 +/- 2.65 micrograms.h/ml after the latter.,The pharmacokinetics of primaquine in calves after subcutaneous and intravenous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8212522/),[h·μg] / [ml],11.85,107951,DB01087,Primaquine
,8212522,areas under the concentration-time curve,The areas under the concentration-time curve for carboxyprimaquine were similar following either IV or SC administration of primaquine; the values were 11.85 +/- 2.62 micrograms.h/ml after the former and 10.95 +/- 2.65 micrograms.h/ml after the latter.,The pharmacokinetics of primaquine in calves after subcutaneous and intravenous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8212522/),[h·μg] / [ml],10.95,107952,DB01087,Primaquine
less,8212522,area under the concentration-time curve,The mean area under the concentration-time curve for primaquine was less than 0.1 micrograms.h/ml after either route of administration.,The pharmacokinetics of primaquine in calves after subcutaneous and intravenous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8212522/),[h·μg] / [ml],0.1,107953,DB01087,Primaquine
,33673562,IC50,"After that, we evaluated the potential biological activity of the novel 2-thioxo-imidazolidin-4-one derivative of PQ, which showed relevant in vitro activity against Trypanosoma cruzi (IC50 1.4 μM) compared to PQ (IC50 1.7 μM) and the reference drug benznidazole (IC50 1.6 μM).","Synthesis, Biological Activity and In Silico Pharmacokinetic Prediction of a New 2-Thioxo-Imidazoldidin-4-One of Primaquine. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33673562/),μM,1.4,115949,DB01087,Primaquine
,33673562,IC50,"After that, we evaluated the potential biological activity of the novel 2-thioxo-imidazolidin-4-one derivative of PQ, which showed relevant in vitro activity against Trypanosoma cruzi (IC50 1.4 μM) compared to PQ (IC50 1.7 μM) and the reference drug benznidazole (IC50 1.6 μM).","Synthesis, Biological Activity and In Silico Pharmacokinetic Prediction of a New 2-Thioxo-Imidazoldidin-4-One of Primaquine. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33673562/),μM,1.7,115950,DB01087,Primaquine
,33673562,IC50,"After that, we evaluated the potential biological activity of the novel 2-thioxo-imidazolidin-4-one derivative of PQ, which showed relevant in vitro activity against Trypanosoma cruzi (IC50 1.4 μM) compared to PQ (IC50 1.7 μM) and the reference drug benznidazole (IC50 1.6 μM).","Synthesis, Biological Activity and In Silico Pharmacokinetic Prediction of a New 2-Thioxo-Imidazoldidin-4-One of Primaquine. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33673562/),μM,1.6,115951,DB01087,Primaquine
,3988392,absorption,The mean absorption and elimination half-lives were 0.36 +/- 0.08 and 3.44 +/- 0.37 hours respectively.,Pharmacokinetics of primaquine in rhesus monkeys. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988392/),h,0.36,116585,DB01087,Primaquine
,3988392,elimination half-lives,The mean absorption and elimination half-lives were 0.36 +/- 0.08 and 3.44 +/- 0.37 hours respectively.,Pharmacokinetics of primaquine in rhesus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988392/),h,3.44,116586,DB01087,Primaquine
,4027117,absolute bioavailability,Absorption of primaquine was virtually complete with a mean absolute bioavailability of 0.96 +/- 0.08.,Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027117/),,0.96,118897,DB01087,Primaquine
,4027117,whole blood to plasma concentration ratios,"The mean whole blood to plasma concentration ratios were determined for primaquine (0.81), and for the carboxylic acid metabolite of primaquine (0.84).",Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027117/),,0.,118898,DB01087,Primaquine
,4027117,whole blood to plasma concentration ratios,"The mean whole blood to plasma concentration ratios were determined for primaquine (0.81), and for the carboxylic acid metabolite of primaquine (0.84).",Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027117/),,0,118899,DB01087,Primaquine
,4027117,CL,"Primaquine is a low clearance compound (CL = 24.2 +/- 7.4 l h-1), is extensively distributed into body tissues (V = 242.9 +/- 69.5 l) and is not subject to extensive first pass metabolism.",Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027117/),[l] / [h],24.2,118900,DB01087,Primaquine
,4027117,V,"Primaquine is a low clearance compound (CL = 24.2 +/- 7.4 l h-1), is extensively distributed into body tissues (V = 242.9 +/- 69.5 l) and is not subject to extensive first pass metabolism.",Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027117/),l,242.9,118901,DB01087,Primaquine
,22771236,retention times,"The retention times for primaquine, 8-aminoquinoline and carboxyprimaquine were 3.3, 5.7 and 8.5 min, respectively.",Simultaneous determination of primaquine and carboxyprimaquine in plasma using solid phase extraction and LC-MS assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771236/),min,3.3,126587,DB01087,Primaquine
,22771236,retention times,"The retention times for primaquine, 8-aminoquinoline and carboxyprimaquine were 3.3, 5.7 and 8.5 min, respectively.",Simultaneous determination of primaquine and carboxyprimaquine in plasma using solid phase extraction and LC-MS assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771236/),min,5.7,126588,DB01087,Primaquine
,22771236,retention times,"The retention times for primaquine, 8-aminoquinoline and carboxyprimaquine were 3.3, 5.7 and 8.5 min, respectively.",Simultaneous determination of primaquine and carboxyprimaquine in plasma using solid phase extraction and LC-MS assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771236/),min,8.5,126589,DB01087,Primaquine
<,22771236,Accura,Accuracy for both analytes was <15% (5-500 μg/L).,Simultaneous determination of primaquine and carboxyprimaquine in plasma using solid phase extraction and LC-MS assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771236/),,15,126590,DB01087,Primaquine
<,22771236,run time,"This validated LC-MS method with solid phase extraction facilitates the simultaneous analysis of primaquine and carboxyprimaquine from small volumes of human plasma, with run time <10 min, recovery >85% and sensitivity of 1-2 μg/L.",Simultaneous determination of primaquine and carboxyprimaquine in plasma using solid phase extraction and LC-MS assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771236/),min,10,126591,DB01087,Primaquine
>,22771236,recovery,"This validated LC-MS method with solid phase extraction facilitates the simultaneous analysis of primaquine and carboxyprimaquine from small volumes of human plasma, with run time <10 min, recovery >85% and sensitivity of 1-2 μg/L.",Simultaneous determination of primaquine and carboxyprimaquine in plasma using solid phase extraction and LC-MS assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22771236/),%,85,126592,DB01087,Primaquine
,3675598,Clearance,Clearance of (-)PQ (8.8 +/- 2.9 ml min-1) was significantly greater than that of (+)PQ (5.5 +/- 1.5 ml min-1) and the apparent volumes of distribution of (-)PQ (606 +/- 182 ml) and (+)PQ (930 +/- 171 ml) were significantly different.,The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675598/),[ml] / [min],8.8,126817,DB01087,Primaquine
,3675598,Clearance,Clearance of (-)PQ (8.8 +/- 2.9 ml min-1) was significantly greater than that of (+)PQ (5.5 +/- 1.5 ml min-1) and the apparent volumes of distribution of (-)PQ (606 +/- 182 ml) and (+)PQ (930 +/- 171 ml) were significantly different.,The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675598/),[ml] / [min],5.5,126818,DB01087,Primaquine
,3675598,apparent volumes of distribution,Clearance of (-)PQ (8.8 +/- 2.9 ml min-1) was significantly greater than that of (+)PQ (5.5 +/- 1.5 ml min-1) and the apparent volumes of distribution of (-)PQ (606 +/- 182 ml) and (+)PQ (930 +/- 171 ml) were significantly different.,The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675598/),ml,606,126819,DB01087,Primaquine
,3675598,apparent volumes of distribution,Clearance of (-)PQ (8.8 +/- 2.9 ml min-1) was significantly greater than that of (+)PQ (5.5 +/- 1.5 ml min-1) and the apparent volumes of distribution of (-)PQ (606 +/- 182 ml) and (+)PQ (930 +/- 171 ml) were significantly different.,The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675598/),ml,930,126820,DB01087,Primaquine
,3675598,half-life,"Stereoselectivity in the hepatic elimination efficiency was manifest as a significant reduction in half-life (-)PQ 54 +/- 29 min; (+)PQ 123 +/- 33 min) and smaller area under the curve to infinity (-)PQ 254 +/- 96 micrograms ml-1.min, (+)PQ 387 +/- 108 micrograms ml-1.min) for (-)PQ when compared with (+)PQ.",The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675598/),min,54,126821,DB01087,Primaquine
,3675598,half-life,"Stereoselectivity in the hepatic elimination efficiency was manifest as a significant reduction in half-life (-)PQ 54 +/- 29 min; (+)PQ 123 +/- 33 min) and smaller area under the curve to infinity (-)PQ 254 +/- 96 micrograms ml-1.min, (+)PQ 387 +/- 108 micrograms ml-1.min) for (-)PQ when compared with (+)PQ.",The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675598/),min,123,126822,DB01087,Primaquine
,3675598,area under the curve to infinity,"Stereoselectivity in the hepatic elimination efficiency was manifest as a significant reduction in half-life (-)PQ 54 +/- 29 min; (+)PQ 123 +/- 33 min) and smaller area under the curve to infinity (-)PQ 254 +/- 96 micrograms ml-1.min, (+)PQ 387 +/- 108 micrograms ml-1.min) for (-)PQ when compared with (+)PQ.",The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675598/),[min·μg] / [ml],254,126823,DB01087,Primaquine
,3675598,area under the curve to infinity,"Stereoselectivity in the hepatic elimination efficiency was manifest as a significant reduction in half-life (-)PQ 54 +/- 29 min; (+)PQ 123 +/- 33 min) and smaller area under the curve to infinity (-)PQ 254 +/- 96 micrograms ml-1.min, (+)PQ 387 +/- 108 micrograms ml-1.min) for (-)PQ when compared with (+)PQ.",The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675598/),[min·μg] / [ml],387,126824,DB01087,Primaquine
,3675598,peak concentration,A significantly greater peak concentration of PQm was achieved following administration of (-)PQ (0.61 +/- 0.26 micrograms ml-1.min) than (+)PQ (0.19 +/- 0.09 micrograms ml-1).,The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675598/),[min·μg] / [ml],0.61,126825,DB01087,Primaquine
,3675598,peak concentration,A significantly greater peak concentration of PQm was achieved following administration of (-)PQ (0.61 +/- 0.26 micrograms ml-1.min) than (+)PQ (0.19 +/- 0.09 micrograms ml-1).,The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675598/),[μg] / [ml],0.19,126826,DB01087,Primaquine
,3675598,areas under the curve to 4 hr,There was no difference between the sum of the areas under the curve to 4 hr for (+) and (-)PQ and the corresponding carboxylic acid metabolite (322 +/- 64 micrograms ml-1 and 317 +/- 75 micrograms ml min-1 respectively).,The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675598/),[μg] / [ml],322,126827,DB01087,Primaquine
,3675598,areas under the curve to 4 hr,There was no difference between the sum of the areas under the curve to 4 hr for (+) and (-)PQ and the corresponding carboxylic acid metabolite (322 +/- 64 micrograms ml-1 and 317 +/- 75 micrograms ml min-1 respectively).,The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675598/),[ml·μg] / [min],317,126828,DB01087,Primaquine
,3675598,biliary clearance,There was no difference in the biliary clearance of (+) and (-)PQ (0.08 +/- 0.02 ml min-1 and 0.14 +/- 0.10 ml min-1 respectively) or the corresponding carboxylic acid metabolites (0.24 +/- 0.13 ml min-1 and 0.29 +/- 0.09 ml min-1).,The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675598/),[ml] / [min],0.08,126829,DB01087,Primaquine
,3675598,biliary clearance,There was no difference in the biliary clearance of (+) and (-)PQ (0.08 +/- 0.02 ml min-1 and 0.14 +/- 0.10 ml min-1 respectively) or the corresponding carboxylic acid metabolites (0.24 +/- 0.13 ml min-1 and 0.29 +/- 0.09 ml min-1).,The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675598/),[ml] / [min],0.14,126830,DB01087,Primaquine
,3675598,biliary clearance,There was no difference in the biliary clearance of (+) and (-)PQ (0.08 +/- 0.02 ml min-1 and 0.14 +/- 0.10 ml min-1 respectively) or the corresponding carboxylic acid metabolites (0.24 +/- 0.13 ml min-1 and 0.29 +/- 0.09 ml min-1).,The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675598/),[ml] / [min],0.24,126831,DB01087,Primaquine
,3675598,biliary clearance,There was no difference in the biliary clearance of (+) and (-)PQ (0.08 +/- 0.02 ml min-1 and 0.14 +/- 0.10 ml min-1 respectively) or the corresponding carboxylic acid metabolites (0.24 +/- 0.13 ml min-1 and 0.29 +/- 0.09 ml min-1).,The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675598/),[ml] / [min],0.29,126832,DB01087,Primaquine
,19574014,flow rate,"Effective separation of NP-96, internal standard (IS) and matrix components were achieved on an UHPLC column (Hypersil Gold C18, 50mmx2.1mm, 1.9microm) using a mobile phase composed of acetonitrile and 20mM ammonium acetate, which was pumped in a gradient mode at a flow rate of 450microl/min.","Development and validation of a sensitive and selective UHPLC-MS/MS method for quantitation of an investigational anti-malarial compound, 2-tert-butylprimaquine (NP-96) in rat plasma, and its application in a preclinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19574014/),[μl] / [min],450,127152,DB01087,Primaquine
,19574014,Total runtime,"Total runtime for the method was 5min, which was suitable to produce high-throughput results for pharmacokinetic evaluation.","Development and validation of a sensitive and selective UHPLC-MS/MS method for quantitation of an investigational anti-malarial compound, 2-tert-butylprimaquine (NP-96) in rat plasma, and its application in a preclinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19574014/),min,5,127153,DB01087,Primaquine
> or =,8504623,half-life,"For pentamidine, a long half-life of > or = 4 days implies the need for a loading dose.",Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8504623/),d,4,131379,DB01087,Primaquine
,8504623,Plasma concentrations of,Plasma concentrations of the parent drug at steady-state varied between 30 and 100 micrograms/L.,Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8504623/),[μg] / [l],30 and 100,131380,DB01087,Primaquine
,3893840,half-lives (t1/2 beta),"In healthy subjects, the cinchona alkaloids (quinine and quinidine), primaquine and proguanil (chloroguanide) are all rapidly eliminated with half-lives (t1/2 beta) of between 6 and 12 hours.",Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),h,6 and 12,134980,DB01087,Primaquine
,3893840,t1/2 beta,Chloroquine (t1/2 beta 6 to 50 days) and mefloquine (t1/2 beta 6.5 to 33 days) have extensive tissue distribution and prolonged activity after a single dose.,Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),d,6 to 50,134981,DB01087,Primaquine
,3893840,t1/2 beta,Chloroquine (t1/2 beta 6 to 50 days) and mefloquine (t1/2 beta 6.5 to 33 days) have extensive tissue distribution and prolonged activity after a single dose.,Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),d,6.5 to 33,134982,DB01087,Primaquine
,3893840,t1/2,"Pyrimethamine (t1/2 35 to 175 hours) has more limited tissue distribution, plasma and erythrocyte concentrations are similar, and 85% of the drug in plasma is bound to plasma proteins.",Clinical pharmacokinetics of antimalarial drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),h,35 to 175,134983,DB01087,Primaquine
,26818020,parasite clearance time,"The median parasite clearance time was 24 h in FDC of arterolane maleate and PQP group and 26 h in chloroquine group (Log-rank, p = 0.2264).","Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26818020/),h,24,139831,DB01087,Primaquine
,26818020,parasite clearance time,"The median parasite clearance time was 24 h in FDC of arterolane maleate and PQP group and 26 h in chloroquine group (Log-rank, p = 0.2264).","Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26818020/),h,26,139832,DB01087,Primaquine
,26818020,fever clearance time,"Similarly, median fever clearance time was 24 h in both the groups (Log-rank, p = 0.7750).","Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26818020/),h,24,139833,DB01087,Primaquine
,26818020,t1/2,The pharmacokinetic analysis indicates that arterolane maleate is well absorbed and has a relatively short t1/2 of 3.2 h.,"Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26818020/),h,3.2,139834,DB01087,Primaquine
,26818020,t1/2,Piperaquine is also well absorbed after oral administration with a t1/2 of about 228.33 h.,"Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26818020/),h,228.33,139835,DB01087,Primaquine
,21058417,flow rate,"The enantiomers were well separated using a Chiralcel OD column (250 × 4.6 mm, 10 µm) with a linear gradient of mobile phase consisting of acetonitrile (0.1% formic acid) and aqueous ammonium formate (20 mm; 0.1% formic acid) adjusted to pH 5.9 at a flow rate of 0.7 mL/min.","Analysis of primaquine and its metabolite carboxyprimaquine in biological samples: enantiomeric separation, method validation and quantification. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058417/),[ml] / [min],0.7,144070,DB01087,Primaquine
,21058417,recoveries,"The average recoveries of (-)-(R)- and (+)-(S)-primaquine and (-)-(R)- and (+)-(S)-carboxyprimaquine were 88 and 92%, respectively, in spiked human plasma and 89 and 93% respectively in spiked mouse plasma samples.","Analysis of primaquine and its metabolite carboxyprimaquine in biological samples: enantiomeric separation, method validation and quantification. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058417/),%,88,144071,DB01087,Primaquine
,21058417,recoveries,"The average recoveries of (-)-(R)- and (+)-(S)-primaquine and (-)-(R)- and (+)-(S)-carboxyprimaquine were 88 and 92%, respectively, in spiked human plasma and 89 and 93% respectively in spiked mouse plasma samples.","Analysis of primaquine and its metabolite carboxyprimaquine in biological samples: enantiomeric separation, method validation and quantification. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058417/),%,92,144072,DB01087,Primaquine
,21058417,recoveries,"The average recoveries of (-)-(R)- and (+)-(S)-primaquine and (-)-(R)- and (+)-(S)-carboxyprimaquine were 88 and 92%, respectively, in spiked human plasma and 89 and 93% respectively in spiked mouse plasma samples.","Analysis of primaquine and its metabolite carboxyprimaquine in biological samples: enantiomeric separation, method validation and quantification. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058417/),%,89,144073,DB01087,Primaquine
,21058417,recoveries,"The average recoveries of (-)-(R)- and (+)-(S)-primaquine and (-)-(R)- and (+)-(S)-carboxyprimaquine were 88 and 92%, respectively, in spiked human plasma and 89 and 93% respectively in spiked mouse plasma samples.","Analysis of primaquine and its metabolite carboxyprimaquine in biological samples: enantiomeric separation, method validation and quantification. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058417/),%,93,144074,DB01087,Primaquine
,21058417,RSD,"The RSD of (-)-(R)- and (+)-(S)-primaquine and (-)-(R)- and (+)-(S)-carboxyprimaquine were 2.15, 1.74, 1.73 and 2.31, respectively, in spiked human plasma and 2.21, 1.09, 1.95 and 1.17% in spiked mouse plasma, respectively.","Analysis of primaquine and its metabolite carboxyprimaquine in biological samples: enantiomeric separation, method validation and quantification. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058417/),,2,144075,DB01087,Primaquine
,21058417,RSD,"The RSD of (-)-(R)- and (+)-(S)-primaquine and (-)-(R)- and (+)-(S)-carboxyprimaquine were 2.15, 1.74, 1.73 and 2.31, respectively, in spiked human plasma and 2.21, 1.09, 1.95 and 1.17% in spiked mouse plasma, respectively.","Analysis of primaquine and its metabolite carboxyprimaquine in biological samples: enantiomeric separation, method validation and quantification. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058417/),,1.,144076,DB01087,Primaquine
,21058417,RSD,"The RSD of (-)-(R)- and (+)-(S)-primaquine and (-)-(R)- and (+)-(S)-carboxyprimaquine were 2.15, 1.74, 1.73 and 2.31, respectively, in spiked human plasma and 2.21, 1.09, 1.95 and 1.17% in spiked mouse plasma, respectively.","Analysis of primaquine and its metabolite carboxyprimaquine in biological samples: enantiomeric separation, method validation and quantification. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058417/),,2.,144077,DB01087,Primaquine
,21058417,RSD,"The RSD of (-)-(R)- and (+)-(S)-primaquine and (-)-(R)- and (+)-(S)-carboxyprimaquine were 2.15, 1.74, 1.73 and 2.31, respectively, in spiked human plasma and 2.21, 1.09, 1.95 and 1.17% in spiked mouse plasma, respectively.","Analysis of primaquine and its metabolite carboxyprimaquine in biological samples: enantiomeric separation, method validation and quantification. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058417/),,1.09,144078,DB01087,Primaquine
,24189254,central volume of distribution,The mean PMQ central volume of distribution and clearance relative to bioavailability (200 liters/70 kg and 24.6 liters/h/70 kg) were within published ranges for adults.,Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24189254/),[l] / [70·kg],200,155940,DB01087,Primaquine
,24189254,clearance relative to bioavailability,The mean PMQ central volume of distribution and clearance relative to bioavailability (200 liters/70 kg and 24.6 liters/h/70 kg) were within published ranges for adults.,Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24189254/),[l] / [70·h·kg],24.6,155941,DB01087,Primaquine
,19861604,C(max),"Women had significantly higher median values of C(max) (212 versus 122 ng/mL, P< 0.001) and AUC(0-24) (1,909 versus 917 ng . h/mL, P < 0.001) of primaquine compared with men.",Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861604/),[ng] / [ml],212,164255,DB01087,Primaquine
,19861604,C(max),"Women had significantly higher median values of C(max) (212 versus 122 ng/mL, P< 0.001) and AUC(0-24) (1,909 versus 917 ng . h/mL, P < 0.001) of primaquine compared with men.",Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861604/),[ng] / [ml],122,164256,DB01087,Primaquine
,19861604,AUC(0-24),"Women had significantly higher median values of C(max) (212 versus 122 ng/mL, P< 0.001) and AUC(0-24) (1,909 versus 917 ng . h/mL, P < 0.001) of primaquine compared with men.",Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861604/),[h·ng] / [ml],"1,909",164257,DB01087,Primaquine
,19861604,AUC(0-24),"Women had significantly higher median values of C(max) (212 versus 122 ng/mL, P< 0.001) and AUC(0-24) (1,909 versus 917 ng . h/mL, P < 0.001) of primaquine compared with men.",Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19861604/),[h·ng] / [ml],917,164258,DB01087,Primaquine
,31031463,absorption rate constant (Ka),"Fixed effects parameter estimates of the final model - absorption rate constant (Ka), volume of distribution (V), and clearance (CL) - were 0.95/h, 498 L, and 39 L/h, respectively.",Population pharmacokinetics of primaquine and the effect of hepatic and renal dysfunction: An exploratory approach. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31031463/),1/[h],0.95,165390,DB01087,Primaquine
,31031463,volume of distribution (V),"Fixed effects parameter estimates of the final model - absorption rate constant (Ka), volume of distribution (V), and clearance (CL) - were 0.95/h, 498 L, and 39 L/h, respectively.",Population pharmacokinetics of primaquine and the effect of hepatic and renal dysfunction: An exploratory approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31031463/),l,498,165391,DB01087,Primaquine
,31031463,clearance (CL),"Fixed effects parameter estimates of the final model - absorption rate constant (Ka), volume of distribution (V), and clearance (CL) - were 0.95/h, 498 L, and 39 L/h, respectively.",Population pharmacokinetics of primaquine and the effect of hepatic and renal dysfunction: An exploratory approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31031463/),[l] / [h],39,165392,DB01087,Primaquine
,8070311,Elimination half-life,Elimination half-life for the drug was 30 +/- 14 hr.,Pharmacokinetics and kinetic-dynamic modeling of an 8-aminoquinoline candidate anticyanide and antimalarial drug (WR242511). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070311/),h,30,168122,DB01087,Primaquine
,9682162,recovery,The method was fully validated from 50 to 1600 ng ml-1 concentration range with a recovery ranging from 70 to 75%.,A rapid and sensitive high performance liquid chromatographic assay of the new antimalarial compound 80/53 in serum with a novel sample clean-up method and its pharmacokinetics in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9682162/),%,70 to 75,170716,DB01087,Primaquine
,9682162,terminal half-life,The terminal half-life and MRT of AM were 95.3 +/- 43.5 and 104 +/- 10.6 min respectively.,A rapid and sensitive high performance liquid chromatographic assay of the new antimalarial compound 80/53 in serum with a novel sample clean-up method and its pharmacokinetics in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9682162/),min,95.3,170717,DB01087,Primaquine
,9682162,MRT,The terminal half-life and MRT of AM were 95.3 +/- 43.5 and 104 +/- 10.6 min respectively.,A rapid and sensitive high performance liquid chromatographic assay of the new antimalarial compound 80/53 in serum with a novel sample clean-up method and its pharmacokinetics in rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9682162/),min,104,170718,DB01087,Primaquine
,9682162,MRT,The MRT and AM after oral dose was 31.1+2-8.3 min.,A rapid and sensitive high performance liquid chromatographic assay of the new antimalarial compound 80/53 in serum with a novel sample clean-up method and its pharmacokinetics in rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9682162/),min,31.1,170719,DB01087,Primaquine
,1596283,IC50,"Ketoconazole caused marked inhibition of carboxymefloquine formation with IC50 and Ki values of 7.5 and 11.2 microM, respectively.",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,7.5,176859,DB01087,Primaquine
,1596283,Ki,"Ketoconazole caused marked inhibition of carboxymefloquine formation with IC50 and Ki values of 7.5 and 11.2 microM, respectively.",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,11.2,176860,DB01087,Primaquine
,1596283,IC50,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,17.5,176861,DB01087,Primaquine
,1596283,IC50,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,122,176862,DB01087,Primaquine
,1596283,Ki,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,8.6,176863,DB01087,Primaquine
,1596283,Ki,"Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively).",Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1596283/),μM,28.5,176864,DB01087,Primaquine
,16570188,CL/F,"Estimates [95% confidence interval (CI)] of CL/F, V(ss)/F and t(1/2)(z) were found to be 56.4 (29-84) l/h, 6,000 (3,500-8,500) l and 11.7 (8.3-15.7) days, respectively.",Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16570188/),[l] / [h],56.4,188815,DB01087,Primaquine
,16570188,V(ss)/F,"Estimates [95% confidence interval (CI)] of CL/F, V(ss)/F and t(1/2)(z) were found to be 56.4 (29-84) l/h, 6,000 (3,500-8,500) l and 11.7 (8.3-15.7) days, respectively.",Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16570188/),l,"6,000",188816,DB01087,Primaquine
,16570188,t(1/2)(z),"Estimates [95% confidence interval (CI)] of CL/F, V(ss)/F and t(1/2)(z) were found to be 56.4 (29-84) l/h, 6,000 (3,500-8,500) l and 11.7 (8.3-15.7) days, respectively.",Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16570188/),d,11.7,188817,DB01087,Primaquine
,1447338,detection limit,The detection limit was 0.01 microgram/ml in plasma for all three compounds.,"High-performance liquid chromatographic determination of pamaquine, primaquine and carboxy primaquine in calf plasma using electrochemical detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1447338/),[μg] / [ml],0.01,189061,DB01087,Primaquine
,33146311,half-life,"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),d,9.5,197054,DB01087,Primaquine
,33146311,half-life,"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),d,10.2,197055,DB01087,Primaquine
,33146311,maximum concentration (Cmax),"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),[ng] / [ml],1295,197056,DB01087,Primaquine
,33146311,maximum concentration (Cmax),"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),[ng] / [ml],1220,197057,DB01087,Primaquine
,33146311,area-under-the-curve (AUC 0-28),"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),[μg] / [h·ml],241,197058,DB01087,Primaquine
,33146311,area-under-the-curve (AUC 0-28),"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),[μg] / [h·ml],237,197059,DB01087,Primaquine
,33146311,observed clearance (CL/f),"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),[l] / [h],5.8,197060,DB01087,Primaquine
,33146311,observed clearance (CL/f),"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),[l] / [h],5.5,197061,DB01087,Primaquine
,33146311,volume of distribution (V/f),"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),l,1869,197062,DB01087,Primaquine
,33146311,volume of distribution (V/f),"The pharmacokinetic parameters of chloroquine were similar between male and female patients: a half-life of 9.5 days and 10.2 days, maximum concentration (Cmax) of 1295 ng/ml and 1220 ng/ml, area-under-the-curve (AUC 0-28) of 241 µg/mL h and 237 µg/mL h, observed clearance (CL/f) of 5.8 and 5.5 L/h and the volume of distribution (V/f) of 1869 L and 1936 L.",Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33146311/),l,1936,197063,DB01087,Primaquine
,16760502,maximum plasma concentration,"No statistical differences were observed in the following kinetic parameters of primaquine between men and women, respectively: maximum plasma concentration (93 +/- 26 and 115 +/- 38 ng/mL; 95% confidence interval [CI] of the mean difference: -55 to 10 ng/mL; P = 0.16), area under the curve (1.1 +/- 0.5 and 1.2 +/- 0.4 microg x h/mL; 95% CI: -0.6 to 0.3 microg x h/mL; P = 0.54), and clearance (0.34 +/- 0.12 and 0.39 +/- 0.14 L/h/kg; 95% CI: -0.17 to 0.08 L/h/kg; P = 0.46).",Lack of sex effect on the pharmacokinetics of primaquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16760502/),[ng] / [ml],93,210890,DB01087,Primaquine
,16760502,maximum plasma concentration,"No statistical differences were observed in the following kinetic parameters of primaquine between men and women, respectively: maximum plasma concentration (93 +/- 26 and 115 +/- 38 ng/mL; 95% confidence interval [CI] of the mean difference: -55 to 10 ng/mL; P = 0.16), area under the curve (1.1 +/- 0.5 and 1.2 +/- 0.4 microg x h/mL; 95% CI: -0.6 to 0.3 microg x h/mL; P = 0.54), and clearance (0.34 +/- 0.12 and 0.39 +/- 0.14 L/h/kg; 95% CI: -0.17 to 0.08 L/h/kg; P = 0.46).",Lack of sex effect on the pharmacokinetics of primaquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16760502/),[ng] / [ml],115,210891,DB01087,Primaquine
,16760502,area under the curve,"No statistical differences were observed in the following kinetic parameters of primaquine between men and women, respectively: maximum plasma concentration (93 +/- 26 and 115 +/- 38 ng/mL; 95% confidence interval [CI] of the mean difference: -55 to 10 ng/mL; P = 0.16), area under the curve (1.1 +/- 0.5 and 1.2 +/- 0.4 microg x h/mL; 95% CI: -0.6 to 0.3 microg x h/mL; P = 0.54), and clearance (0.34 +/- 0.12 and 0.39 +/- 0.14 L/h/kg; 95% CI: -0.17 to 0.08 L/h/kg; P = 0.46).",Lack of sex effect on the pharmacokinetics of primaquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16760502/),[h·μg] / [ml],1.1,210892,DB01087,Primaquine
,16760502,area under the curve,"No statistical differences were observed in the following kinetic parameters of primaquine between men and women, respectively: maximum plasma concentration (93 +/- 26 and 115 +/- 38 ng/mL; 95% confidence interval [CI] of the mean difference: -55 to 10 ng/mL; P = 0.16), area under the curve (1.1 +/- 0.5 and 1.2 +/- 0.4 microg x h/mL; 95% CI: -0.6 to 0.3 microg x h/mL; P = 0.54), and clearance (0.34 +/- 0.12 and 0.39 +/- 0.14 L/h/kg; 95% CI: -0.17 to 0.08 L/h/kg; P = 0.46).",Lack of sex effect on the pharmacokinetics of primaquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16760502/),[h·μg] / [ml],1.2,210893,DB01087,Primaquine
,16760502,clearance,"No statistical differences were observed in the following kinetic parameters of primaquine between men and women, respectively: maximum plasma concentration (93 +/- 26 and 115 +/- 38 ng/mL; 95% confidence interval [CI] of the mean difference: -55 to 10 ng/mL; P = 0.16), area under the curve (1.1 +/- 0.5 and 1.2 +/- 0.4 microg x h/mL; 95% CI: -0.6 to 0.3 microg x h/mL; P = 0.54), and clearance (0.34 +/- 0.12 and 0.39 +/- 0.14 L/h/kg; 95% CI: -0.17 to 0.08 L/h/kg; P = 0.46).",Lack of sex effect on the pharmacokinetics of primaquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16760502/),[l] / [h·kg],0.34,210894,DB01087,Primaquine
,16760502,clearance,"No statistical differences were observed in the following kinetic parameters of primaquine between men and women, respectively: maximum plasma concentration (93 +/- 26 and 115 +/- 38 ng/mL; 95% confidence interval [CI] of the mean difference: -55 to 10 ng/mL; P = 0.16), area under the curve (1.1 +/- 0.5 and 1.2 +/- 0.4 microg x h/mL; 95% CI: -0.6 to 0.3 microg x h/mL; P = 0.54), and clearance (0.34 +/- 0.12 and 0.39 +/- 0.14 L/h/kg; 95% CI: -0.17 to 0.08 L/h/kg; P = 0.46).",Lack of sex effect on the pharmacokinetics of primaquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16760502/),[l] / [h·kg],0.39,210895,DB01087,Primaquine
,27639847,Cmax,"The pharmacokinetic parameters of chloroquine analysed in whole blood dry spot samples showed mean (coefficient of variation) Cmax and AUC0-t values of 374.44 (0.35) and 3700.43 (0.36) ng/mL, respectively.","Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27639847/),[ng] / [ml],374.44,223504,DB01087,Primaquine
,27639847,AUC0-t,"The pharmacokinetic parameters of chloroquine analysed in whole blood dry spot samples showed mean (coefficient of variation) Cmax and AUC0-t values of 374.44 (0.35) and 3700.43 (0.36) ng/mL, respectively.","Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27639847/),[ng] / [ml],3700.43,223505,DB01087,Primaquine
,2784984,half-lives,"There were no significant differences between the respective groups in the half-lives (2.5 +/- 1.5, 2.2 +/- 1.1 h), AUCs (0.43 +/- 0.14, 0.372 +/- 0.096 microgram.h ml-1), clearances (19.0 +/- 5.4, 21.1 +/- 4.2 ml h-1), and apparent volume of distribution (78.9 +/- 28.1, 76.2 +/- 31.7 ml).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),h,2.5,227502,DB01087,Primaquine
,2784984,half-lives,"There were no significant differences between the respective groups in the half-lives (2.5 +/- 1.5, 2.2 +/- 1.1 h), AUCs (0.43 +/- 0.14, 0.372 +/- 0.096 microgram.h ml-1), clearances (19.0 +/- 5.4, 21.1 +/- 4.2 ml h-1), and apparent volume of distribution (78.9 +/- 28.1, 76.2 +/- 31.7 ml).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),h,2.2,227503,DB01087,Primaquine
,2784984,AUCs,"There were no significant differences between the respective groups in the half-lives (2.5 +/- 1.5, 2.2 +/- 1.1 h), AUCs (0.43 +/- 0.14, 0.372 +/- 0.096 microgram.h ml-1), clearances (19.0 +/- 5.4, 21.1 +/- 4.2 ml h-1), and apparent volume of distribution (78.9 +/- 28.1, 76.2 +/- 31.7 ml).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),[h·μg] / [ml],0.43,227504,DB01087,Primaquine
,2784984,AUCs,"There were no significant differences between the respective groups in the half-lives (2.5 +/- 1.5, 2.2 +/- 1.1 h), AUCs (0.43 +/- 0.14, 0.372 +/- 0.096 microgram.h ml-1), clearances (19.0 +/- 5.4, 21.1 +/- 4.2 ml h-1), and apparent volume of distribution (78.9 +/- 28.1, 76.2 +/- 31.7 ml).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),[h·μg] / [ml],0.372,227505,DB01087,Primaquine
,2784984,clearances,"There were no significant differences between the respective groups in the half-lives (2.5 +/- 1.5, 2.2 +/- 1.1 h), AUCs (0.43 +/- 0.14, 0.372 +/- 0.096 microgram.h ml-1), clearances (19.0 +/- 5.4, 21.1 +/- 4.2 ml h-1), and apparent volume of distribution (78.9 +/- 28.1, 76.2 +/- 31.7 ml).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),[ml] / [h],19.0,227506,DB01087,Primaquine
,2784984,clearances,"There were no significant differences between the respective groups in the half-lives (2.5 +/- 1.5, 2.2 +/- 1.1 h), AUCs (0.43 +/- 0.14, 0.372 +/- 0.096 microgram.h ml-1), clearances (19.0 +/- 5.4, 21.1 +/- 4.2 ml h-1), and apparent volume of distribution (78.9 +/- 28.1, 76.2 +/- 31.7 ml).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),[ml] / [h],21.1,227507,DB01087,Primaquine
,2784984,apparent volume of distribution,"There were no significant differences between the respective groups in the half-lives (2.5 +/- 1.5, 2.2 +/- 1.1 h), AUCs (0.43 +/- 0.14, 0.372 +/- 0.096 microgram.h ml-1), clearances (19.0 +/- 5.4, 21.1 +/- 4.2 ml h-1), and apparent volume of distribution (78.9 +/- 28.1, 76.2 +/- 31.7 ml).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),ml,78.9,227508,DB01087,Primaquine
,2784984,apparent volume of distribution,"There were no significant differences between the respective groups in the half-lives (2.5 +/- 1.5, 2.2 +/- 1.1 h), AUCs (0.43 +/- 0.14, 0.372 +/- 0.096 microgram.h ml-1), clearances (19.0 +/- 5.4, 21.1 +/- 4.2 ml h-1), and apparent volume of distribution (78.9 +/- 28.1, 76.2 +/- 31.7 ml).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),ml,76.2,227509,DB01087,Primaquine
,2784984,total bile production,"In the presence of mefloquine, total bile production was significantly reduced (1244.5 +/- 317.1 microliters) compared with primaquine alone (1621.5 +/- 174.2 microliters).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),μl,1244.5,227510,DB01087,Primaquine
,2784984,total bile production,"In the presence of mefloquine, total bile production was significantly reduced (1244.5 +/- 317.1 microliters) compared with primaquine alone (1621.5 +/- 174.2 microliters).",Primaquine disposition in the isolated perfused rat liver: effect of mefloquine induced bile flow reduction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784984/),μl,1621.5,227511,DB01087,Primaquine
,34299634,retention times,"The retention times of 5,6-PQ and PQ in plasma and urine were 0.8 and 1.6 min, respectively.","Simplified and Rapid Determination of Primaquine and 5,6-Orthoquinone Primaquine by UHPLC-MS/MS: Its Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34299634/),min,0.8,233112,DB01087,Primaquine
,34299634,retention times,"The retention times of 5,6-PQ and PQ in plasma and urine were 0.8 and 1.6 min, respectively.","Simplified and Rapid Determination of Primaquine and 5,6-Orthoquinone Primaquine by UHPLC-MS/MS: Its Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34299634/),min,1.6,233113,DB01087,Primaquine
,34299634,recovery,"The recovery of PQ and 5,6-PQ ranged from 78% to 95% and form 80% to 98% for plasma, and from 102% to from 112% to 97% to 109% for urine, respectively.","Simplified and Rapid Determination of Primaquine and 5,6-Orthoquinone Primaquine by UHPLC-MS/MS: Its Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34299634/),%,78,233114,DB01087,Primaquine
,34299634,recovery,"The recovery of PQ and 5,6-PQ ranged from 78% to 95% and form 80% to 98% for plasma, and from 102% to from 112% to 97% to 109% for urine, respectively.","Simplified and Rapid Determination of Primaquine and 5,6-Orthoquinone Primaquine by UHPLC-MS/MS: Its Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34299634/),%,95,233115,DB01087,Primaquine
,34299634,recovery,"The recovery of PQ and 5,6-PQ ranged from 78% to 95% and form 80% to 98% for plasma, and from 102% to from 112% to 97% to 109% for urine, respectively.","Simplified and Rapid Determination of Primaquine and 5,6-Orthoquinone Primaquine by UHPLC-MS/MS: Its Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34299634/),%,80,233116,DB01087,Primaquine
,34299634,recovery,"The recovery of PQ and 5,6-PQ ranged from 78% to 95% and form 80% to 98% for plasma, and from 102% to from 112% to 97% to 109% for urine, respectively.","Simplified and Rapid Determination of Primaquine and 5,6-Orthoquinone Primaquine by UHPLC-MS/MS: Its Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34299634/),%,98,233117,DB01087,Primaquine
,34299634,recovery,"The recovery of PQ and 5,6-PQ ranged from 78% to 95% and form 80% to 98% for plasma, and from 102% to from 112% to 97% to 109% for urine, respectively.","Simplified and Rapid Determination of Primaquine and 5,6-Orthoquinone Primaquine by UHPLC-MS/MS: Its Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34299634/),%,102,233118,DB01087,Primaquine
,34299634,recovery,"The recovery of PQ and 5,6-PQ ranged from 78% to 95% and form 80% to 98% for plasma, and from 102% to from 112% to 97% to 109% for urine, respectively.","Simplified and Rapid Determination of Primaquine and 5,6-Orthoquinone Primaquine by UHPLC-MS/MS: Its Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34299634/),%,112,233119,DB01087,Primaquine
,34299634,recovery,"The recovery of PQ and 5,6-PQ ranged from 78% to 95% and form 80% to 98% for plasma, and from 102% to from 112% to 97% to 109% for urine, respectively.","Simplified and Rapid Determination of Primaquine and 5,6-Orthoquinone Primaquine by UHPLC-MS/MS: Its Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34299634/),%,97,233120,DB01087,Primaquine
,34299634,recovery,"The recovery of PQ and 5,6-PQ ranged from 78% to 95% and form 80% to 98% for plasma, and from 102% to from 112% to 97% to 109% for urine, respectively.","Simplified and Rapid Determination of Primaquine and 5,6-Orthoquinone Primaquine by UHPLC-MS/MS: Its Application to a Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34299634/),%,109,233121,DB01087,Primaquine
,28836792,zeta potential,The mean particle size of Gel-LA-PQ-NPs was found to be 93.48 ± 6.36 nm with a zeta potential of 4.80 ± 0.20 mV having 69.90 ± 1.53% encapsulation efficiency.,Galactose-Anchored Gelatin Nanoparticles for Primaquine Delivery and Improved Pharmacokinetics: A Biodegradable and Safe Approach for Effective Antiplasmodial Activity against P. falciparum 3D7 and in Vivo Hepatocyte Targeting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28836792/),mv,4.80,238098,DB01087,Primaquine
,28836792,IC50,The in vitro antiplasmodium assay revealed that the IC50 value against the blood stage of asexual P. falciparum 3D7 strains was significantly (p < 0.01) less (2.862 ± 0.103 μM) for Gel-LA-PQ-NPs than naïve PQ (3.879 ± 0.655 μM).,Galactose-Anchored Gelatin Nanoparticles for Primaquine Delivery and Improved Pharmacokinetics: A Biodegradable and Safe Approach for Effective Antiplasmodial Activity against P. falciparum 3D7 and in Vivo Hepatocyte Targeting. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28836792/),μM,2.862,238099,DB01087,Primaquine
,28836792,IC50,The in vitro antiplasmodium assay revealed that the IC50 value against the blood stage of asexual P. falciparum 3D7 strains was significantly (p < 0.01) less (2.862 ± 0.103 μM) for Gel-LA-PQ-NPs than naïve PQ (3.879 ± 0.655 μM).,Galactose-Anchored Gelatin Nanoparticles for Primaquine Delivery and Improved Pharmacokinetics: A Biodegradable and Safe Approach for Effective Antiplasmodial Activity against P. falciparum 3D7 and in Vivo Hepatocyte Targeting. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28836792/),μM,3.879,238100,DB01087,Primaquine
,8443039,peak plasma concentrations,"2. Primaquine was rapidly absorbed, attaining peak plasma concentrations (median and range) of 167 (113-532) micrograms l-1 in 2 (1-4) h.","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[μg] / [l],167,242272,DB01087,Primaquine
,8443039,apparent terminal half-life,"Thereafter, concentrations declined rapidly with an apparent terminal half-life of 6.1 (1.7-16.1) h and an oral clearance (CLpo) of 33.1 (17.6-49.3) l h-1.","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),h,6.1,242273,DB01087,Primaquine
,8443039,oral clearance (CLpo),"Thereafter, concentrations declined rapidly with an apparent terminal half-life of 6.1 (1.7-16.1) h and an oral clearance (CLpo) of 33.1 (17.6-49.3) l h-1.","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[l] / [h],33.1,242274,DB01087,Primaquine
,8443039,Cmax,"Administration of mefloquine had no effect on the values of any of these parameters at the 5% level of significance [Cmax 229 (114-503) micrograms l-1; tmax 3 (2-4) h; t1/2,z 3.9 (1.7-13.5) h; CLpo 34.0 (21.7-49.0) l h-1].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[μg] / [l],229,242275,DB01087,Primaquine
,8443039,tmax,"Administration of mefloquine had no effect on the values of any of these parameters at the 5% level of significance [Cmax 229 (114-503) micrograms l-1; tmax 3 (2-4) h; t1/2,z 3.9 (1.7-13.5) h; CLpo 34.0 (21.7-49.0) l h-1].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),h,3,242276,DB01087,Primaquine
,8443039,"t1/2,z","Administration of mefloquine had no effect on the values of any of these parameters at the 5% level of significance [Cmax 229 (114-503) micrograms l-1; tmax 3 (2-4) h; t1/2,z 3.9 (1.7-13.5) h; CLpo 34.0 (21.7-49.0) l h-1].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),h,3.9,242277,DB01087,Primaquine
,8443039,CLpo,"Administration of mefloquine had no effect on the values of any of these parameters at the 5% level of significance [Cmax 229 (114-503) micrograms l-1; tmax 3 (2-4) h; t1/2,z 3.9 (1.7-13.5) h; CLpo 34.0 (21.7-49.0) l h-1].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[l] / [h],34.0,242278,DB01087,Primaquine
,8443039,maximum concentrations,3. The carboxylic acid metabolite of primaquine achieved maximum concentrations (median and range) of 890 (553-3634) micrograms l-1 at 6 (3-16) h.,"Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[μg] / [l],890,242279,DB01087,Primaquine
,8443039,"AUC (0,24 h)","AUC (0,24 h) was 12737 (6837-27388) micrograms l-1 h.","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[h·μg] / [l],12737,242280,DB01087,Primaquine
,8443039,Cmax,"Administration of mefloquine had no effect on the plasma concentrations of this metabolite [Cmax 1035 (174-3015) micrograms l-1; tmax 8 (2-24) h; AUC(0,24) 13471 (2132-17863) micrograms l-1 h].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[μg] / [l],1035,242281,DB01087,Primaquine
,8443039,tmax,"Administration of mefloquine had no effect on the plasma concentrations of this metabolite [Cmax 1035 (174-3015) micrograms l-1; tmax 8 (2-24) h; AUC(0,24) 13471 (2132-17863) micrograms l-1 h].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),h,8,242282,DB01087,Primaquine
,8443039,"AUC(0,24)","Administration of mefloquine had no effect on the plasma concentrations of this metabolite [Cmax 1035 (174-3015) micrograms l-1; tmax 8 (2-24) h; AUC(0,24) 13471 (2132-17863) micrograms l-1 h].","Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8443039/),[h·μg] / [l],13471,242283,DB01087,Primaquine
,3383988,half-life,Sulphaphenazole produced a significant increase in the half-life of tolbutamide (7.10 to 21.50 h) and a corresponding decrease in its clearance (0.260 to 0.084 ml.min-1.kg-1).,"Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),h,7.10 to 21.50,243330,DB01087,Primaquine
,3383988,clearance,Sulphaphenazole produced a significant increase in the half-life of tolbutamide (7.10 to 21.50 h) and a corresponding decrease in its clearance (0.260 to 0.084 ml.min-1.kg-1).,"Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),[ml] / [kg·min],0.260 to 0.084,243331,DB01087,Primaquine
,3383988,half lives,"However, a 1.6-times higher dose of cimetidine did increase the half lives both of tolbutamide and antipyrine (6.21 to 9.04 h and 14.2 to 19.2 h, respectively) and decrease their clearance (0.226 to 0.148 and 0.50 to 0.31 ml.min-1 kg-1, respectively).","Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),h,6.21 to 9.04,243332,DB01087,Primaquine
,3383988,half lives,"However, a 1.6-times higher dose of cimetidine did increase the half lives both of tolbutamide and antipyrine (6.21 to 9.04 h and 14.2 to 19.2 h, respectively) and decrease their clearance (0.226 to 0.148 and 0.50 to 0.31 ml.min-1 kg-1, respectively).","Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),h,14.2 to 19.2,243333,DB01087,Primaquine
,3383988,clearance,"However, a 1.6-times higher dose of cimetidine did increase the half lives both of tolbutamide and antipyrine (6.21 to 9.04 h and 14.2 to 19.2 h, respectively) and decrease their clearance (0.226 to 0.148 and 0.50 to 0.31 ml.min-1 kg-1, respectively).","Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),[ml] / [kg·min],0.226 to 0.148,243334,DB01087,Primaquine
,3383988,clearance,"However, a 1.6-times higher dose of cimetidine did increase the half lives both of tolbutamide and antipyrine (6.21 to 9.04 h and 14.2 to 19.2 h, respectively) and decrease their clearance (0.226 to 0.148 and 0.50 to 0.31 ml.min-1 kg-1, respectively).","Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),[ml] / [kg·min],0.50 to 0.31,243335,DB01087,Primaquine
,3383988,half-life,A single dose of primaquine had no demonstrable effect on tolbutamide disposition whereas the half-life of antipyrine was increased (12.1 to 15.0 h) and its clearance decreased (0.63 to 0.38 ml.min-1.kg-1).,"Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),h,12.1 to 15.0,243336,DB01087,Primaquine
,3383988,clearance,A single dose of primaquine had no demonstrable effect on tolbutamide disposition whereas the half-life of antipyrine was increased (12.1 to 15.0 h) and its clearance decreased (0.63 to 0.38 ml.min-1.kg-1).,"Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),[ml] / [kg·min],0.63 to 0.38,243337,DB01087,Primaquine
,24014905,Cmax,"The Cmax [median (range) in ng/ml] was 29.3 (14.6-104.3), 40.3 (14.8 - 78.6), and 49.8 (15 - 169.6) and the tmax [median (range) in hours] was 3.0 (1.0- 6.0), 2.0 (1.5 - 8) and 2.0 (1.0 - 4.0) for healthy and stage IV, V (not on dialysis) CKD participants, respectively.",Pharmacokinetics of single-dose primaquine in patients with chronic kidney dysfunction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24014905/),[ng] / [ml],29.3,245481,DB01087,Primaquine
,24014905,Cmax,"The Cmax [median (range) in ng/ml] was 29.3 (14.6-104.3), 40.3 (14.8 - 78.6), and 49.8 (15 - 169.6) and the tmax [median (range) in hours] was 3.0 (1.0- 6.0), 2.0 (1.5 - 8) and 2.0 (1.0 - 4.0) for healthy and stage IV, V (not on dialysis) CKD participants, respectively.",Pharmacokinetics of single-dose primaquine in patients with chronic kidney dysfunction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24014905/),[ng] / [ml],40.3,245482,DB01087,Primaquine
,24014905,Cmax,"The Cmax [median (range) in ng/ml] was 29.3 (14.6-104.3), 40.3 (14.8 - 78.6), and 49.8 (15 - 169.6) and the tmax [median (range) in hours] was 3.0 (1.0- 6.0), 2.0 (1.5 - 8) and 2.0 (1.0 - 4.0) for healthy and stage IV, V (not on dialysis) CKD participants, respectively.",Pharmacokinetics of single-dose primaquine in patients with chronic kidney dysfunction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24014905/),[ng] / [ml],49.8,245483,DB01087,Primaquine
,24014905,tmax,"The Cmax [median (range) in ng/ml] was 29.3 (14.6-104.3), 40.3 (14.8 - 78.6), and 49.8 (15 - 169.6) and the tmax [median (range) in hours] was 3.0 (1.0- 6.0), 2.0 (1.5 - 8) and 2.0 (1.0 - 4.0) for healthy and stage IV, V (not on dialysis) CKD participants, respectively.",Pharmacokinetics of single-dose primaquine in patients with chronic kidney dysfunction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24014905/),h,3.0,245484,DB01087,Primaquine
,24014905,tmax,"The Cmax [median (range) in ng/ml] was 29.3 (14.6-104.3), 40.3 (14.8 - 78.6), and 49.8 (15 - 169.6) and the tmax [median (range) in hours] was 3.0 (1.0- 6.0), 2.0 (1.5 - 8) and 2.0 (1.0 - 4.0) for healthy and stage IV, V (not on dialysis) CKD participants, respectively.",Pharmacokinetics of single-dose primaquine in patients with chronic kidney dysfunction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24014905/),h,2.0,245485,DB01087,Primaquine
,24014905,tmax,"The Cmax [median (range) in ng/ml] was 29.3 (14.6-104.3), 40.3 (14.8 - 78.6), and 49.8 (15 - 169.6) and the tmax [median (range) in hours] was 3.0 (1.0- 6.0), 2.0 (1.5 - 8) and 2.0 (1.0 - 4.0) for healthy and stage IV, V (not on dialysis) CKD participants, respectively.",Pharmacokinetics of single-dose primaquine in patients with chronic kidney dysfunction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24014905/),h,2.0,245486,DB01087,Primaquine
,12659609,maximum serum concentration,Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.,Toxicity related to chloroquine treatment of resistant vivax malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659609/),[μg] / [l],902,256908,DB01087,Primaquine
,16722829,CL/F,The mean CL/F of primaquine was slightly higher in males than in females [0.52 l h(-1) kg(-1)vs.,"Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects? ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16722829/),[l] / [h·kg],0.52,258853,DB01087,Primaquine
,6639836,half-life,"Primaquine (45 mg) given 2 h before antipyrine (300 mg orally), increased antipyrine half-life (calculated from 0-24 h) from 12.7 +/- 3.2 (mean +/- s.d.) to 25.3 +/- 3.9 h and decreased clearance from 3.01 +/- 0.67 to 1.32 +/- 0.32 1 h-1.",Effect of chloroquine and primaquine on antipyrine metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639836/),h,12.7,259538,DB01087,Primaquine
,6639836,half-life,"Primaquine (45 mg) given 2 h before antipyrine (300 mg orally), increased antipyrine half-life (calculated from 0-24 h) from 12.7 +/- 3.2 (mean +/- s.d.) to 25.3 +/- 3.9 h and decreased clearance from 3.01 +/- 0.67 to 1.32 +/- 0.32 1 h-1.",Effect of chloroquine and primaquine on antipyrine metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639836/),h,25.3,259539,DB01087,Primaquine
,6639836,clearance,"Primaquine (45 mg) given 2 h before antipyrine (300 mg orally), increased antipyrine half-life (calculated from 0-24 h) from 12.7 +/- 3.2 (mean +/- s.d.) to 25.3 +/- 3.9 h and decreased clearance from 3.01 +/- 0.67 to 1.32 +/- 0.32 1 h-1.",Effect of chloroquine and primaquine on antipyrine metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639836/),[1] / [h],3.01,259540,DB01087,Primaquine
,6639836,clearance,"Primaquine (45 mg) given 2 h before antipyrine (300 mg orally), increased antipyrine half-life (calculated from 0-24 h) from 12.7 +/- 3.2 (mean +/- s.d.) to 25.3 +/- 3.9 h and decreased clearance from 3.01 +/- 0.67 to 1.32 +/- 0.32 1 h-1.",Effect of chloroquine and primaquine on antipyrine metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639836/),[1] / [h],1.32,259541,DB01087,Primaquine
,7721226,apparent volume of distribution,Mefloquine has a large apparent volume of distribution of 200 L and is highly bound (98%) to plasma proteins.,Clinical application of mefloquine pharmacokinetics in the treatment of P falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721226/),l,200,260923,DB01087,Primaquine
,7721226,terminal half-life,The elimination is slow; the terminal half-life is 13 10 to 14 days in Thai patients with falciparum malaria.,Clinical application of mefloquine pharmacokinetics in the treatment of P falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721226/),d,13 10 to 14,260924,DB01087,Primaquine
,29590311,maximum value,"In 20 mother-infant pairs, primaquine concentrations were below measurement thresholds in all but 1 infant capillary plasma sample (that contained primaquine 2.6 ng/mL), and carboxyprimaquine was likewise unmeasurable in the majority of infant samples (maximum value 25.8 ng/mL).",Primaquine Pharmacokinetics in Lactating Women and Breastfed Infant Exposures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29590311/),[ng] / [ml],25.8,263757,DB01087,Primaquine
,22185941,area under curve,Total PQ exposure in beagle dogs was 2.2 times higher (area under curve of 12 193 versus 5678 ng h/ml) and the elimination half-life of PQ was a 19-fold greater (12.95 hours versus 0.68 hours) with the extended-release tablets compared with the immediate-release tablets.,Increased bioavailability of primaquine using poly(ethylene oxide) matrix extended-release tablets administered to beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22185941/),[h·ng] / [ml],12 193,268431,DB01087,Primaquine
,22185941,area under curve,Total PQ exposure in beagle dogs was 2.2 times higher (area under curve of 12 193 versus 5678 ng h/ml) and the elimination half-life of PQ was a 19-fold greater (12.95 hours versus 0.68 hours) with the extended-release tablets compared with the immediate-release tablets.,Increased bioavailability of primaquine using poly(ethylene oxide) matrix extended-release tablets administered to beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22185941/),[h·ng] / [ml],5678,268432,DB01087,Primaquine
,22185941,elimination half-life,Total PQ exposure in beagle dogs was 2.2 times higher (area under curve of 12 193 versus 5678 ng h/ml) and the elimination half-life of PQ was a 19-fold greater (12.95 hours versus 0.68 hours) with the extended-release tablets compared with the immediate-release tablets.,Increased bioavailability of primaquine using poly(ethylene oxide) matrix extended-release tablets administered to beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22185941/),h,12.95,268433,DB01087,Primaquine
,22185941,elimination half-life,Total PQ exposure in beagle dogs was 2.2 times higher (area under curve of 12 193 versus 5678 ng h/ml) and the elimination half-life of PQ was a 19-fold greater (12.95 hours versus 0.68 hours) with the extended-release tablets compared with the immediate-release tablets.,Increased bioavailability of primaquine using poly(ethylene oxide) matrix extended-release tablets administered to beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22185941/),h,0.68,268434,DB01087,Primaquine
